Biomoda, Inc. (OTCBB: BMOD) received Notice of Allowance for a U.S. Patent issued today that expands on use of the CyPath® assay to include patient response to cancer therapy during the treatment phase of the disease.
According to John Cousins, President of Biomoda, “Our pilot clinical study demonstrated the CyPath® assay’s utility as a cancer diagnostic. We expect the unique properties of the CyPath® labeling solution that allow it to bind to cancer cells and cause them to fluoresce can also play a significant role in determining the efficacy of cancer treatment. Doctors will be able to take fluid or tissue samples at intervals during chemotherapy, treat them with the CyPath® solution and compare the results to the baseline assay to see if the percentage of cancerous and abnormal cells is moving in the right direction.”